摘要
目的 分析江苏省南京地区2017-2019年37家医院抗乙肝病毒药物的临床应用情况，为临床使用提供参考依据。方法 分别采用用药频度（DDDs）与金额排序法，对37家南京各级医院2017-2019年使用的抗乙肝病毒药物的品种、销售金额、构成比、DDDs、限定日费用（DDC）等进行回顾性分析和统计。结果 2017-2019年，抗乙肝病毒药物在南京地区的年销售金额呈下降，平均下降率为5.19%；年DDDs逐年增长，平均增长率为9.17%；恩替卡韦的销售金额与DDDs值连续三年位居榜首，占年总销售金额、DDDs值比例三年来均超过55%。恩替卡韦与替诺福韦连续三年B/A值为1，阿德福韦酯、拉米夫定以及替比夫定的DDDs值呈现下降趋势，但是其他药物均表现为上升趋势。结论 抗乙肝病毒药物在南京地区医院整体应用较广，药品的销售金额整体上略微下降但其使用量呈上升的趋势，大部分药物的DDC为降低趋势。
关键词： 乙型肝炎病毒；销售金额；用药频度；限定日费用；药物利用
Abstract
Objective: This study was designed to analyze the application of Anti-hepatitis B virus drugs in 37 hospitals in Nanjing from 2017 to 2019 and provide a reference for its clinical. Methods: Using the medication frequency (DDDs) and the sum of money of consumption(DDC), to analysis the varieties, sales amount, composition ratio, medication frequency and daily drug cost of Anti-hepatitis B virus drugs in 37 hospitals in Nanjing in the study of Retrospective statistics. Results: The total amount of use of Anti-hepatitis B virus drugs had decreased year by year, with an average annual declining rate of 5.19%. But the DDDs of use of Anti-hepatitis B virus drugs had increased year by year, with an average annual growth rate of 9.17%. The three-year sales and DDDs of Entecavir was ranked in the top one, and the proportion was more than 55%.B/A values of Entecavir is one in three years. Conclusion : The Anti-hepatitis B virus drugs are widely used in hospitals in Nanjing, the sales amount and usage as a whole showed a trend of stabilization after growth, and the vast majority of daily drug cost is decreasing.
Key words： Anti-hepatitis B virus; Sales amount of money; DDDs; DDC; Medical analyze
参考文献 References
[1] Liu J, Liang W, Jing W, et al. Countdown to 2030: eliminating hepatitis B disease, China[J]. Bull World Health Organ. 2019,3,1,97(3):230-238.
[2] Smolders EJ, Burger DM, Feld JJ, et al. Review article: clinical pharmacology of current and investigational hepatitis B virus therapies[J]. Aliment Pharmacol Ther. 2020,1,51(2):231-243.
[3] WHO Collaborating Centre for Drug Statistics Methodology. Vpdates included in the ATC/DDD index[EB/OL].(2018-11-26)[2019-11-30].https://www.whocc.no/atc_ddd_index/updates_included_in_the_atc_ddd_index.
[4] 国家药典委员会.中华人民共和国药典药典[M].2020版.北京：中国医药科技出版社.
[5] 陈新谦,金有豫,汤光,等.新编药物学[M].第17版.北京:人民卫生出版社,2011:416-425.
[6] Yuen MF, Chen DS, Dusheiko GM,et al. Hepatitis B virus infection[J]. Nat Rev Dis Primers. 2018,6,7，4:18035.
[7] Boffito M, Waters L, Cahn P, et al. Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection[J]. AIDS Res Hum Retroviruses. 2020 Jan，36(1):13-18.
[8] 陆群.南通大学附属第三医院2017—2019年核苷（酸）类似物抗乙型肝炎病毒药物使用情况分析[J].临床合理用药杂志,2020,13(33):17-20+24.
[9] 吴丹娜,王敏,韩方璇,等.2010-2014年南京地区核苷类抗病毒用药分析[J].中华医院感染学杂志, 2016, 26 (23): 5364-5366+5370.
[10] 陈萍.抗乙肝病毒核苷类药物治疗乙肝病毒研究新进展[J].北方药学,2016,13(01):93-94.
[11] Zhu S, Yang YH, Gao RW, et al. Clinical features of hypophosphatemic osteomalacia induced by long-term low-dose adefovir dipivoxil[J]. Drug Des Devel Ther. 2017 Dec 27，12:41-45.
[12] 马洪斌.慢性乙型病毒性肝炎抗HBV病毒治疗现状及研究进展分析[J].继续医学教育,2019,33(05):145-147.
[13] Xiang Q, Liu Z, Yu Y, et al. Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose Adefovir Dipivoxil: a case report[J]. BMC Pharmacol Toxicol. 2020 Jun 5，21(1):43.
[14] 萨可佳,王金叶,陈瑞家,等.我院2017～2019年口服抗乙肝病毒药物用药分析[J].海峡药学,2020,32(01):200-201.
[15] Tenney DJ, Rose RE, Baldick CJ, et al. Colonno RJ. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy[J].Hepatology.2009 May，49(5):1503-14
[16] 徐炼红.单用替诺福韦酯与单用恩替卡韦治疗慢性乙型肝炎的临床疗效刍议[J].世界复合医学,2020, 6(01): 187-189.
[17] De Clercq E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)[J]. Biochem Pharmacol. 2016,11,1，119:1-7.
[18] 何美芝,谢玥,王汇敏,等.乙型肝炎病毒感染特殊人群的抗病毒治疗新进展[J].实用医学杂志, 2019, 35 (10):1529-1533.
[19] 娄晓月,侯婷婷,苗薇薇,等.抗乙肝药物研究现状[J].现代医学与健康研究电子杂志,2019,3(11):12-13.
[20] 王哈申其其格.慢性乙肝病毒感染的治疗进展应用研究[J].国际感染病学(电子版),2020,9(02):337-338.